SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

AbbVie stock fell after denying Revolution Medicines buyout talks. Company also cut 2025 earnings forecast to $9.90-$9.94 per ...

Millions rely on Medicare Part D, but many prescription drugs won't be covered in 2026. See which meds are excluded, why, and ...

Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple ...

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...

A South Dakota law that prevents drug companies from restricting federal drug discounts for hospitals and other providers ...

Jan ‌7 (Reuters) - ​AbbVie is ‌in ​advanced ‍talks to ​buy ​cancer-drug developer ⁠Revolution Medicines, the ‌Wall Street ...

Maryland’s Prescription Drug Affordability Board (PDAB) serves as a bellwether for how other states may address high drug ...

Medicare Part D coverage is never static, but 2026 is shaping up to be a particularly volatile year for formularies.

AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines, the Wall Street Journal reported on Wednesday, ...